drugset
drugset / Trial / NCT02428608

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006

NCT02428608 ↗

Phase 2 Completed 570 enrolled Evolus, Inc. PPD Development, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult subjects.

Timeline

Start
2015-05
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PrabotulinumtoxinA Protein / enzyme biologic — —

Indications

No indication recorded.